Drug Discovery and Development (DDD)

SciLifeLab National platform Since 2013.

Primary: Shown in the list of current labels, if end date is not specified.

Started: 2013

Ended: Current

Year 2024

N-(Heteroaryl)thiophene sulfonamides as angiotensin AT2 receptor ligands.
Wannberg J, Gising J, Henriksson M, ..., Hallberg M, Larhed M
Eur J Med Chem 265 (-) 116122 [2024-02-05; online 2024-01-03]
Drug Discovery and Development (DDD) [Collaborative]

Year 2023

Year 2022

Year 2021

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes.
Byrgazov K, Lind T, Rasmusson AJ, ..., Larsson R, Fryknäs M
Bone Rep 15 (-) 101098 [2021-12-00; online 2021-06-07]
Drug Discovery and Development (DDD)
ENABLE: an engine for European antibacterial drug discovery and development.
Olliver M, Griestop L, Hughes D, ..., Vingsbo Lundberg C, Karlén A
Nat Rev Drug Discov 20 (6) 407-408 [2021-06-00; online 2021-05-06]
Drug Discovery and Development (DDD) [Collaborative]

Year 2020

High content drug screening for Fanconi anemia therapeutics.
Montanuy H, Camps-Fajol C, Carreras-Puigvert J, ..., Minguillón J, Surrallés J
Orphanet J Rare Dis 15 (1) 170 [2020-06-30; online 2020-06-30]
Drug Discovery and Development (DDD)

Year 2019

Year 2018

Year 2017

Targeting tumor cells based on Phosphodiesterase 3A expression.
Nazir M, Senkowski W, Nyberg F, ..., Larsson R, Fryknäs M
Exp. Cell Res. 361 (2) 308-315 [2017-12-15; online 2017-10-26]
Drug Discovery and Development (DDD) [Service]
Corrigendum: MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
Gad H, Koolmeister T, Jemth AS, ..., Scobie M, Ulrika Warpman Berglund &Thomas Helleday
Nature 544 (7651) 508 [2017-04-26; online 2017-04-28]
Drug Discovery and Development (DDD) [Service]

Year 2016

Iron chelators target both proliferating and quiescent cancer cells.
Fryknäs M, Zhang X, Bremberg U, ..., Linder S, Larsson R
Sci Rep 6 (-) 38343 [2016-12-07; online 2016-12-07]
Drug Discovery and Development (DDD) [Service]
Case-specific potentiation of glioblastoma drugs by pterostilbene.
Schmidt L, Baskaran S, Johansson P, ..., Krona C, Nelander S
Oncotarget 7 (45) 73200-73215 [2016-11-08; online 2016-10-01]
Drug Discovery and Development (DDD) [Collaborative]
A Facile Synthesis of NODASA-Functionalized Peptide
Naicker T, Albericio F, Dutta J, ..., Kruger H, Govender T
Synlett 27 (11) 1685-1688 [2016-03-30; online 2016-03-30]
Drug Discovery and Development (DDD) [Collaborative]
On-Water Synthesis of Biaryl Sulfonyl Fluorides.
Chinthakindi PK, Kruger HG, Govender T, Naicker T, Arvidsson PI
J. Org. Chem. 81 (6) 2618-2623 [2016-03-18; online 2016-02-24]
Drug Discovery and Development (DDD) [Collaborative]
Stereoselective synthesis towards unnatural proline based amino acids
S.Makhathini S, Das SK, Singh T, ..., Govender T, Naicker T
ARKIVOC 2016 (3) 134-144 [2016-02-07; online 2016-02-07]
Drug Discovery and Development (DDD) [Collaborative]

Year 2015

Synthesis of enantiopure angiotensin II type 2 receptor [AT2R] antagonist EMA401
Wakchaure PB, Bremberg U, Wannberg J, Larhed M
Tetrahedron 71 (38) 6881-6887 [2015-09-00; online 2015-09-00]
Drug Discovery and Development (DDD)
NOTA: a potent metallo-β-lactamase inhibitor.
Somboro AM, Tiwari D, Bester LA, ..., Naicker T, Essack SY
J. Antimicrob. Chemother. 70 (5) 1594-1596 [2015-05-00; online 2015-01-06]
Drug Discovery and Development (DDD) [Collaborative]

Year 2014

Year 2013


Publications 9.5.1